Pace Biotech

Surajpur, Paonta sahib Dist. Sirmour (H.P)

Add Pace To Health

ace

:

Title

Certificate of Analysis Finished Product

| CLOCIVIR 500MG Injection | A.R. No. | NB/FP/23/329 |
|--------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Sampled qty. | 45 vials |
| | Sampled by | Aakash |
| | Sampled on | 19/12/2023 |
| | Date of Testing | 19/12/2023 |
| | Date of Release | 03/01/2024 |
| | CLOCIVIR 500MG Injection Acyclovir Intravenous Infusion IP 500mg N23271G 6613 Vials 10/2023 09/2025 | Choch virte source injectionSampled qty.Acyclovir Intravenous Infusion IP 500mgSampled qty.N23271GSampled by6613 VialsSampled on10/2023Date of Testing |

| S. No. | Tests | Specifications | Observations A white dry powder filled in |
|--------|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|
| 1. | Description | A white or almost white, crystalline powder filled in clear glass vial. | |
| 2. | Identification | A . When examined in the range 230 nm to 360 nm the solution prepared in the Assay shows an absorption maximum at about 255 nm and a broad shoulder at about 274 nm. | Complies |
| | and the state of the states | B . In the test of Guanine, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with | Complies |
| | n Asselson Sodium | reference solution (a). C. It gives reaction of Sodium salts. | Complies |
| 3. | Uniformity of weight | Average weight ±10% | -1.83% & +2.82% |
| 4. | Average weight | Informative. | 600.1 mg |
| 5. | Particulate Matter (a.) Sub-Visible particle count (1.) Particles ≥10µm (2.) Particles ≥25µm (b.) Visual | NMT-6000/vial NMT-600/vial The solution should be essentially free from extraneous, mobile undissolved particles, other than gas bubbles, unintentionally. | - Company in |
| 6. | Appearance of solution | The solution is not more opalescent than opalescence standard OS2, and not more intensely coloured than reference solution BYS5. | |
| 7. | pH | 10.7 to 11.7 | 11.63 |
| 8. | Related Substances (By TLC) | Any secondary spot with an R _F value greater than that of the principal spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (0.5 per cent). | |

Pace Biotech

ce To Health

•

Citle

Surajpur, Paonta sahib Dist. Sirmour (H.P)

Certificate of Analysis Finished Product

| Product Name | CLOCIVIR 500MG Injection | A.R. No. | NB/FP/23/329 |
|--------------|-----------------------------------------|-----------------|--------------|
| Generic Name | Acyclovir Intravenous Infusion IP 500mg | Sampled qty. | 45 vials |
| Batch No. | N23271G | Sampled by | Aakash |
| Batch Size | 6613 Vials | Sampled on | 19/12/2023 |
| Mfg. Date | 10/2023 | Date of Testing | 19/12/2023 |
| Exp. Date | 09/2025 | Date of Release | 03/01/2024 |

| 9. | Guanine | Any secondary spot corresponding | | | Observa | Complies | |
|---------------------------------------------|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----|---------------------------------------------------------|-------------------------------|--|
| | Alemification | to guanine in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (b) (1.0 per cent). | | | A white dry possier interes charges rich Complies | | |
| 10. | Sterility | No microbial growth should be observed. | | | Complies | | |
| 11. | Bacterial Endotoxins | e . | | | Less than Acyclovi | an- 0.174 EU/mg of vir. | |
| 12. | Assay : Each glass vial Contains | obtained with test solution (b) | | | | | |
| Ingredients | | Labeled Claim | Found | | f labeled mount | Limits % of labeled amount | |
| (Sterile) Acyclovir Sodium (Lyophilized) | | C. It gives read | ion of Sedaue s | dte | | Complies | |
| Eq. to | Acyclovir IP | 500 mg | 506.25 mg | 10 |)1.25% | 95.0% to 105.0% | |

Remarks: In the opinion of the undersigned the sample referred to above is/ is-not of the standard quality as The Drug & Cosmetic Act 1940 and the rules made there under. Complies/ not complies as per IP/BP/USP/IHS.

Checked by Analysis by